Overview

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

Status:
Not yet recruiting

Trial end date:
2030-02-18

Target enrollment:

Participant gender:

Summary

The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

ADC Therapeutics S.A.

Treatments:

Cyclophosphamide
Doxorubicin
Loncastuximab tesirine
Prednisone
Rituximab
Vincristine